API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 6 sources · 26 days · First seen · Last updated

Pacira BioSciences corporate acquisitions

Overview

Pacira BioSciences has undergone significant structural changes through multiple acquisitions. In October 2026, Viatris entered a definitive agreement to acquire Pacira BioSciences in an all-cash transaction valued at approximately $1.65 billion. This acquisition aimed to incorporate Pacira’s non-opioid pain therapies, specifically Exparel and Zilretta, into the Viatris portfolio.

In November 2026, Zimmer Biomet agreed to acquire the Iovera business from Pacira BioSciences. The deal is valued at up to $140 million, consisting of a $70 million upfront payment and up to $70 million in revenue-based milestone payments through 2031. The Iovera system uses cold therapy to provide targeted, non-opioid pain relief for patients with knee pain or those undergoing joint replacement surgery. This acquisition is intended to strengthen Zimmer Biomet’s orthopaedics portfolio. The sale was intended to allow Pacira BioSciences to focus on its core biopharmaceutical business and its existing pipeline of non-opioid pain therapies.

Entities

Pacira BioSciences · Iovera · Scott Smith · Zimmer Biomet · Zilretta

Timeline

  1. [BUSINESS] 6 sources
    Zimmer Biomet to acquire Pacira BioSciences’ Iovera device

    Zimmer Biomet is acquiring Pacira BioSciences’ Iovera device for up to $140 million while reporting Q3 2026 earnings that beat analyst revenue and profit expectations.

  2. [BUSINESS] 3 sources
    Viatris to acquire Pacira BioSciences for $1.65 billion

    Viatris is acquiring Pacira BioSciences for $1.65 billion to add non-opioid pain therapies Exparel and Zilretta to its portfolio, aiming to provide alternatives to traditional opioid treatments.

Sources

ad-hoc-news.de · digitalhealth.london · finance.technews.tw · newsable.asianetnews.com · theascent.com · unilorin.edu.ng

This summary has been updated 1 time: see revision history